Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Immune & inflammatory · 2024

Ebglyss (lebrikizumab-lbkz)

The FDA approved Ebglyss (lebrikizumab-lbkz) on September 13, 2024 to treat moderate-to-severe atopic dermatitis.
Brand name
Ebglyss
Generic name
lebrikizumab-lbkz
FDA approval date
September 13, 2024
Approved use (FDA wording)
To treat moderate-to-severe atopic dermatitis
Category on this site
Immune & inflammatory

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.